Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes
文献类型：期刊论文
| 作者 | Wang, Jian2; Wu, Zhitao1; Pan, Guoyu1 ; Ni, Junsheng2; Xie, Fangyuan3,5; Jiang, Beige2; Wei, Lixin6; Gao, Jie3,4; Zhou, Weiping2
|
| 刊名 | NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
 |
| 出版日期 | 2018-08 |
| 卷号 | 14期号:6页码:1949-1961 |
| 关键词 | CD147 Antibody Liposomes Doxorubicin Hepatocellular carcinoma |
| ISSN号 | 1549-9634 |
| DOI | 10.1016/j.nano.2017.09.012 |
| 文献子类 | Article |
| 英文摘要 | HAb18G/CD147, an important marker in the progression of hepatocellular carcinoma (HCC), is highly expressed on the surface of HCC cells. To increase the therapeutic efficacy of Doxil (PECiylated liposomal doxorubicin) against HCC, we constructed CD147-targeted doxonthicin-loaded immunoliposomes (Anti-CD147 ILs-DOX) by conjugating F(ab')2 of a CD147-specific monoclonal antibody to DSPEPEG-MAL, and then inserted the antibody-conjugated polymer to Doxil. Anti-CD147 ILs-DOX delivered DOX to CD147-overexpressing HCC cells specifically and efficiently in vitro and in vivo, resulting in enhanced therapeutic effects than non-targeted controls. Strikingly, Anti-CD147 ILs-DOX reduced the CD133-positive fraction of HCC cells, suggesting its potential in reducing the number of HCC stem cells. Pharmacokinetic and biodistribution studies of Anti-CD147 ILs-DOX confirmed its long circulation time and efficient accumulation in tumors. The superior antitumor effects of Anti-CD147 ILs-DOX than other treatments were demonstrated in both HCC cells and patient-derived HCC xenograft models. Anti-CD147 ILs-DOX represent a novel approach for targeted HCC, therapy. (C) 2018 Elsevier Inc. All rights reserved. |
| WOS关键词 | CANCER STEM/PROGENITOR CELLS ; TARGETED IMMUNOLIPOSOMES ; TUMOR-LOCALIZATION ; IN-VIVO ; EFFICACY ; DRUGS ; BIODISTRIBUTION ; HETEROGENEITY ; NANOPARTICLES ; XENOGRAFTS |
| 资助项目 | National "973" project of China[2014CB542102] ; Science Fund for Creative Research Groups[00000000] ; National Natural Science Foundation of China (NSFC)[81521091] ; National Natural Science Foundation of China (NSFC)[81771964] ; National Natural Science Foundation of China (NSFC)[81472829] |
| WOS研究方向 | Science & Technology - Other Topics ; Research & Experimental Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:000439366100019 |
| 出版者 | ELSEVIER SCIENCE BV |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/279647]  |
| 专题 | 药物安全性评价中心 |
| 通讯作者 | Jiang, Beige; Wei, Lixin; Gao, Jie; Zhou, Weiping |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Materia Med, Shanghai, Peoples R China; 2.Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 3, Shanghai, Peoples R China; 3.Second Mil Med Univ, Dept Pharmaceut Sci, Shanghai, Peoples R China; 4.Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA; 5.Second Mil Med Univ, Shanghai Eastern Hepatobiliary Surg Hosp, Dept Pharm, Shanghai, Peoples R China; 6.Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Tumor Immunol & Gene Therapy Ctr, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Jian,Wu, Zhitao,Pan, Guoyu,et al. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes[J]. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE,2018,14(6):1949-1961. |
| APA | Wang, Jian.,Wu, Zhitao.,Pan, Guoyu.,Ni, Junsheng.,Xie, Fangyuan.,...&Zhou, Weiping.(2018).Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE,14(6),1949-1961. |
| MLA | Wang, Jian,et al."Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes".NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 14.6(2018):1949-1961. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。